Last $4.30 USD
Change Today +0.13 / 3.12%
Volume 522.7K
NEO On Other Exchanges
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

neogenomics inc (NEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - $4.69
52 Week Low
08/19/13 - $2.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEOGENOMICS INC (NEO)

Related News

No related news articles were found.

neogenomics inc (NEO) Related Businessweek News

No Related Businessweek News Found

neogenomics inc (NEO) Details

NeoGenomics, Inc., together with its subsidiary, NeoGenomics Laboratories, Inc., operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company performs analyses for hematopoietic cancers, such as leukemia and lymphoma; and solid tumor cancers comprising breast, lung, colon, and bladder cancer. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry testing services to identify cell proteins in a tissue section; and molecular testing services that focus on the analysis of DNA and RNA, as well as on the structure and function of genes at the molecular level. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

315 Employees
Last Reported Date: 05/8/14
Founded in 2001

neogenomics inc (NEO) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $557.0K
Chief Financial Officer
Total Annual Compensation: $305.5K
Chief Medical Officer and Director of Researc...
Total Annual Compensation: $92.5K
Chief Compliance Officer, Executive Vice Pres...
Total Annual Compensation: $72.5K
Chief Scientific Officer
Total Annual Compensation: $331.6K
Compensation as of Fiscal Year 2013.

neogenomics inc (NEO) Key Developments

Neogenomics Inc.(NasdaqCM:NEO) dropped from Russell 2000 Index

Neogenomics Inc. will be removed from the Russell 2000 Index.

Neogenomics Inc.(NasdaqCM:NEO) dropped from Russell 3000 Index

Neogenomics Inc. will be removed from the Russell 3000 Index.

NeoGenomics, Inc. Revises Earnings Guidance for the Second Quarter of 2014

NeoGenomics Inc. revised earnings guidance for the second quarter of 2014. The company announced that it was raising its previously issued revenue guidance for second quarter of 2014. The company now expects revenue of approximately $20.0 million - $20.5 million for the second quarter of 2014 compared with its previous estimate of $18.8 million - $19.3 million. The company also reaffirmed its previously issued earnings per share guidance of $0.00 - $0.01 for the quarter.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEO:US $4.30 USD +0.13

NEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cancer Genetics Inc $10.18 USD +0.20
Foundation Medicine Inc $24.75 USD -1.05
Response Genetics Inc $0.88 USD +0.02
Rosetta Genomics Ltd $3.96 USD +0.23
Signal Genetics Inc $5.90 USD -0.1395
View Industry Companies

Industry Analysis


Industry Average

Valuation NEO Industry Range
Price/Earnings 100.0x
Price/Sales 3.0x
Price/Book 9.2x
Price/Cash Flow 97.2x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOGENOMICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at